meningitis, tetanus, leprosy,

download meningitis, tetanus, leprosy,

of 39

Transcript of meningitis, tetanus, leprosy,

  • 7/29/2019 meningitis, tetanus, leprosy,

    1/39

    COMMUNICABLE DISEASES THAT

    AFFECTS OUR NERVOUS SYSTEM

  • 7/29/2019 meningitis, tetanus, leprosy,

    2/39

    MENINGITIS

    Also known as

    cerebrospinal fever

    Meningitis is theinflammation of the

    meninges of the brain and spinal cord as aresult of viral and bacterial infection.

    Such inflammation may involve the threemeningeal membranes the dura matter, thearachnoid, and the pia matter.

  • 7/29/2019 meningitis, tetanus, leprosy,

    3/39

    WHAT CAUSES MENINGITIS?

    The disease can be caused by several

    kinds of organisms which include the

    pneumococcus, staphylococcus, andtubercle bacillus. The specie Neisseria

    meningitides (meningococcus) is the

    organism causing most epidemics ofmeningitis

  • 7/29/2019 meningitis, tetanus, leprosy,

    4/39

    MENINGOCCCUS

    Human pathogen Non-motile diplococci

    Small, kidney-bean

    Shaped cells

    Non-spore forming

    Optimum growth in

    Warm, moist environment

    Aerobic Gram-negative

    Strongly oxidase positive

    Oxidative metabolism

    Neisseriaminigitides

  • 7/29/2019 meningitis, tetanus, leprosy,

    5/39

    MENINGOCOCCUS CONT

    Energy obtained by Fermentation of varioussugars (N. meningitidis ferments glucose &maltose)

    No Gas is Produced

    Intracellular Growth Habit

    Fastidious ( growth is inhibited by free fattyacids )

    Susceptible to Drying Several of Neisseria are found in aquatic

    environments

    Incubation period varies, the extreme limit being

    set from 1-10 days

  • 7/29/2019 meningitis, tetanus, leprosy,

    6/39

    BACTERIA ACTION

    Neisseria meningitidis is often transferred

    from person to person in aerosol form as

    from a sneeze. Upon infection, it first takes

    residence on the muscosal membranesurface as in the nose, throat, and

    respiratory tract by attaching with its pili. It

    then gradually infects deeper into the tissueuntil it gains access to the bloodstream

    where it then travels to infect the meninges

    of the brain.

  • 7/29/2019 meningitis, tetanus, leprosy,

    7/39

    HOW CAN IT BE TRANSFERRED?

    By respiratory droplets through

    nasopharyngeal mucosa ( droplet

    transmission)

    By direct invasion through otitis media

    (vehicle transmission, Cotton buds)

    May result after a skull fructure, a penetrating

    head wound, lumbar puncture or ventricular

    shunting preocedures

  • 7/29/2019 meningitis, tetanus, leprosy,

    8/39

    SIGNS AND SYMPTOMS

    Symptoms usually come on quickly, and

    may include:

    Fever and chills

    Mental status changes

    Nausea and vomiting

    Sensitivity to light (photophobia)

    Severe headache

    Stiff neck (meningismus)

  • 7/29/2019 meningitis, tetanus, leprosy,

    9/39

    S/S CONT

    Other symptoms that can occur with this

    disease:

    Agitation

    Bulging fontanels

    Decreased consciousness

  • 7/29/2019 meningitis, tetanus, leprosy,

    10/39

    S/S CONT

    Poor feeding or

    irritability in children

    Rapid breathing

    Unusual posture, with

    the head and neck

    arched backwards

    (opisthotonos)

  • 7/29/2019 meningitis, tetanus, leprosy,

    11/39

    DIAGNOSTIC PROCEDURES

    Lumbar puncture

    diagnostic purposes

    To obtain specimen, the CSF

    To take x-ray of the spinal canal and cord

    Therapeutic purposes

    to reduce intra-cranial pressure

    to introduce serum and other medicationsTo inject an anesthetic agent

  • 7/29/2019 meningitis, tetanus, leprosy,

    12/39

    DIAGNOSTIC PROCEDURES CONT

    Gram staining

    Smear and blood culture

    Smear for petechiaeUrine culture

  • 7/29/2019 meningitis, tetanus, leprosy,

    13/39

    MANAGEMENT AND TREATMENT

    1. If meningitis is left untreated it has a mortality rate of 70 to 100per cent.

    2. Treatment includes appropriate antibiotic therapy and vigoroussupportive care.

    3. Usually IV antibiotics are given for 2wks. and are followed by oral

    antibiotics such as: ampicillin, cephalosporin (ceftriaxone),aminoglycosides.

    4. Digitalis glycoside (digoxin) is administered to control arrhythmias.

    5. Mannitol is given to decrease cerebral edema

    6. anticonvulsant or sedative is needed to reduce restlessness and

    convulsions.7. Acetaminophen is helpful to relieve headache and fever.

    8. Asses neurologic sign often. Observe the patients level ofconsciousness and check for increase intra-cranial pressure.

  • 7/29/2019 meningitis, tetanus, leprosy,

    14/39

    MANAGEMENT & TREATMENT CONT

    9. Monitor fluid balance. Maintain adequate fluid intake to avoiddehydration, but avoid fluid overload because of the danger ofcerebral edema. Measure central venous pressure and intakeand output.

    10. Position the patient carefully to prevent joint stiffness and neck

    pain. Turn the patient often to avoid pressure sores andrespiratory complications. Assist with ROM.

    Tests that may be done include:

    Blood culture

    Chest x-ray

    CSF examination for cell count, glucose, and protein CT scan of the head

    Gram stain, other special stains, and culture of CSF

  • 7/29/2019 meningitis, tetanus, leprosy,

    15/39

    PREVENTION

    Haemophilus vaccine (HiB vaccine) in children will help preventone type of meningitis.

    The pneumococcal conjugate vaccine is now a routine childhoodimmunization and is very effective at preventing pneumococcalmeningitis.

    Household members and others in close contact with people whohave meningococcal meningitis should receive preventiveantibiotics to avoid becoming infected themselves.

    The meningococcal vaccination is recommended for:

    Adolescents ages 11 - 12 and adolescents entering high school(about age 15) who have not already received the vaccination.

    All college freshmen who have not been vaccinated and areliving in dorms.

    Children age 2 and older who do not have their spleen or whohave other problems with their immune system.

  • 7/29/2019 meningitis, tetanus, leprosy,

    16/39

    TETANUS

    Tetanus is an infectious disease caused by

    Clostridium tetani which produces potentexotoxin with prominent systemicneuromuscular efforts manifested bygeneralized spasmodic contractions of the

    skeletal musculator

  • 7/29/2019 meningitis, tetanus, leprosy,

    17/39

    TETANUS CONT

    Tetanus is fatal up to 66% of unimmunized

    persons, usually within 10 days onset.

    When symptoms develop within three days,

    the prognosis is poor.

  • 7/29/2019 meningitis, tetanus, leprosy,

    18/39

    WHAT CAUSES TETANUS?

    The causative organism of the disease is

    Clostr id ium tetani .

    Sources of infection are:

    animal and human feces. The organisms are

    found in the intestinal wall of herbivorous

    animals, including man.

    Soil and dustPlaster of paris, unsterile sutures, pins, rusty

    materials, scissors.

  • 7/29/2019 meningitis, tetanus, leprosy,

    19/39

    CLOSTRIDIUM TETANI Anaerobic, gram positive with

    round terminal spore withslender body giving a drumstickappearance.

    The organism comes in 2forms, spore forming and thevegetative form.

    Clostridium tetanireproducesvia an asexual reproductionprocess known as binary

    fission. In this process a singlebacterium cell that has reachedits maximal growth stagedivides into two smalleridentical clone bacteria cells.

    Due to this process, C.

  • 7/29/2019 meningitis, tetanus, leprosy,

    20/39

    CONT

    Incubation period is within 3 days to 3 weeks.

    The organism releases 2 types of toxin:

    Tetanospasmin that is responsible for muscle

    spasm

    Tetanolysin that is responsiblefor destruction of

    RBC.

  • 7/29/2019 meningitis, tetanus, leprosy,

    21/39

    ACTION

    Spores of the bacteria C. tetanilive in the soil and arefound around the world. In the spore form, C.tetanimay remain inactive in the soil, but it canremain infectious for more than 40 years.

    Infection begins when the spores enter the bodythrough an injury orwound. The spores releasebacteria that spread and make a poison calledtetanospasmin. This poison blocks nerve signals from

    the spinal cord to the muscles, causing severemuscle spasms. The spasms can be so powerful thatthey tear the muscles or cause fractures of the spine.

    http://www.ncbi.nlm.nih.gov/pubmedhealth/n/pmh_adam/A002307/http://www.ncbi.nlm.nih.gov/pubmedhealth/n/pmh_adam/A000043/http://www.ncbi.nlm.nih.gov/pubmedhealth/n/pmh_adam/A000001/http://www.ncbi.nlm.nih.gov/pubmedhealth/n/pmh_adam/A000001/http://www.ncbi.nlm.nih.gov/pubmedhealth/n/pmh_adam/A000043/http://www.ncbi.nlm.nih.gov/pubmedhealth/n/pmh_adam/A002307/
  • 7/29/2019 meningitis, tetanus, leprosy,

    22/39

    ACTION

    The time between infection and the first sign

    of symptoms is typically 7 to 21 days

    The toxin (tetanospasmin) has a great affinity

    to the central nervous system tissues and the

    spinal motor ganglia, inducing

    hyperexcitability of the motor neurons by

    interfering with the release of inhibitorytransmitter.

  • 7/29/2019 meningitis, tetanus, leprosy,

    23/39

    HOW CAN IT BE TRANSFERRED?

    Normally, the mode of transmission isthrough punctured wound that iscontaminated by dust, soil, or animal excretacontaining Cl. Tetan i

    1. Rugged traumatic wounds and burns 2. Umbilical stump in newborn especially for

    babies delivered at home with faulty corddressing; babies delivered without tetanus

    toxoid immunization 3. Unrecognized wounds (cleansing of the ears

    with sharp materials)

    4. Dental extraction, circumcision, ear piercing.

  • 7/29/2019 meningitis, tetanus, leprosy,

    24/39

    SIGNS AND SYMPTOMS

    Tetanus often begins with mildspasms in the jaw muscles(lockjaw). The spasms canalso affect the chest, neck,

    back, and abdominal muscles.Back muscle spasms oftencause arching, calledopisthotonos.

    Sometimes the spasms affectmuscles that help withbreathing, which can lead tobreathing problems.

  • 7/29/2019 meningitis, tetanus, leprosy,

    25/39

    S/S CONT

    Polronged muscularaction causessudden, powerful,

    and painfulcontractions ofmuscle groups. Thisis called tetany.

    These episodes cancause fractures andmuscle tears.

  • 7/29/2019 meningitis, tetanus, leprosy,

    26/39

    S/S CONT

    Other symptoms include:

    Drooling

    Excessive sweating

    Fever

    Hand or foot spasms

    Irritability

    Swallowing difficulty

    Uncontrolled urination or defecation

  • 7/29/2019 meningitis, tetanus, leprosy,

    27/39

    MANAGEMENT AND TREATMENT

    Antibiotics, including penicillin, clindamycin,erythromycin, or metronidazole (metronidazole hasbeen most successful)

    Bedrest with a nonstimulating environment (dim light,

    reduced noise, and stable temperature) Medicine to reverse the poison (tetanus immune

    globulin)

    Muscle relaxers such as diazepam

    Sedatives Surgery to clean the wound and remove the source of

    the poison (debridement)

    Breathing support with oxygen, a breathing tube, anda breathing machine may be necessary.

  • 7/29/2019 meningitis, tetanus, leprosy,

    28/39

    PREVENTION

    1. Active immunization with tetanus toxoid for adults 2. DPT for babies and children.

    Tetanus is completely preventable by active tetanusimmunization. Immunization is thought to provide

    protection for 10 years. Studies of soldiers suggestthat good protection persists up to 12 years after thelast immunization.

    Immunizations begin in infancy with the DTaP seriesof shots. The DTaP vaccine is a "3-in-1" vaccine thatprotects against diphtheria, pertussis, and tetanus. Itis a safer version of an older vaccine known as DTP,which is no longer used in the U.S.

  • 7/29/2019 meningitis, tetanus, leprosy,

    29/39

    PREVENTION CONT

    Td vaccine or Tdap vaccine is used to maintainimmunity in those age 11 and older. Tdapvaccine should be given once, prior to age 65,as a substitute for Td for those who have nothad Tdap. Td boosters are recommended every10 years starting at age 19.

    Older teenagers and adults who have sustained

    injuries, especially puncture-type wounds,should receive booster immunization for tetanusif more than 10 years have passed since thelast booster.

  • 7/29/2019 meningitis, tetanus, leprosy,

    30/39

    PREVENTION CONT

    Thorough cleaning of all injuries and wounds and theremoval of dead or severely injured tissue(debridement), when appropriate, may reduce the riskof developing tetanus. If you have been injured

    outside or in any way that makes contact with soillikely, contact your health care provider regarding thepossible risk for tetanus.

    Many people believe injuries caused by rusty nails

    are the most dangerous. This is true only if the nail isdirty as well as rusty, as is usually the case. It is thedirt on the nail, not the rust, that carries the risk fortetanus.

  • 7/29/2019 meningitis, tetanus, leprosy,

    31/39

    LEPROSY

    Also known as

    Hansens disease

    Leprosy is a disease

    that has been knownsince biblical times. It

    causes skin sores,

    nerve damage, andmuscle weakness

    that gets worse over

    time.

  • 7/29/2019 meningitis, tetanus, leprosy,

    32/39

    WHAT CAUSES LEPROSY?

    Leprosy is caused by the

    bacterium Mycobacter ium leprae. It is not

    very contagious and it has a long incubation

    period (time before symptoms appear), whichmakes it hard to know where or when

    someone caught the disease. Children are

    more likely than adults to get the disease.

  • 7/29/2019 meningitis, tetanus, leprosy,

    33/39

    MYCOBACTERIUM LEPRAE

    Mycobacterium leprae acid fast Gram-positive

    bacterium.

    straight or slightlycurved rod-shapedorganism with parallelsized and rounded ends

    It is an obligateintracellular organismand grows and dividesinside macrophages

    and Schwann cells

  • 7/29/2019 meningitis, tetanus, leprosy,

    34/39

    MYCOBACTERIUM LEPRAE CONT

    . It is further characterised by an extremely

    slow doubling time of 12-14 days, favouring

    temperatures of around 30 degrees C. M.

    leprae is the only species of mycobacteria toinfect peripheral nerves.

    Incubation period of leprosy ranges from 5

    and months to 8 years.

  • 7/29/2019 meningitis, tetanus, leprosy,

    35/39

    ACTION

    Mycobacterium leprae attacks the peripheralnerves, especially the ulnar, radial, posterior-popliteal, anterior-tibial and facial nerves.

    when the bacilli damage the skins finenerves, they cause paralysis and dryness.

    If they attack a large nerve trunk, motornerve damage, weakness and pain occur,followed by peripheral paralysis, muscleparalysis and atrophy.

  • 7/29/2019 meningitis, tetanus, leprosy,

    36/39

    HOW IS IT TRANSFERRED?

    1. Mycobacterium leprae is transmitted

    through respiratory droplets (droplets

    transmission)

    2. inoculation breaks in the skin and possiblythrough environmental contacts.

  • 7/29/2019 meningitis, tetanus, leprosy,

    37/39

    SIGNS AND SYMPTOMS

    Skin lesions that are lighter than your normalskin color

    Lesions have decreased sensation to touch,

    heat, or pain Lesions do not heal after several weeks to

    months

    Muscle weaknessNumbness or lack of feeling in the hands,

    arms, feet, and legs

  • 7/29/2019 meningitis, tetanus, leprosy,

    38/39

    MANAGEMENT AND TREATMENT

    A number of different antibiotics (including dapsone,rifampin, clofazamine, fluoroquinolones, macrolides, andminocycline) are used to kill the bacteria that cause thedisease. More than one antibiotic is often given together.

    Aspirin, prednisone, or thalidomide is used to control

    inflammation. Tests done are:

    Lepromin skin test can be used to tell the two differentforms of leprosy apart, but it is not used to diagnose thedisease

    Skin lesion biopsy

    Skin scraping examination

  • 7/29/2019 meningitis, tetanus, leprosy,

    39/39

    PREVENTION

    Prevention consists of avoiding close

    physical contact with untreated people.

    People on long-term medication become

    noninfectious (they do not transmit theorganism that causes the disease).